BDX is navigating a portfolio transition marked by the Embecta spin-off, which drove a 9.5% YoY revenue decline in 2026Q3, yet gross margin resilience at 46.5% and cumulative operating cash flow of $8.5B versus net income of $3.5B suggest underlying cash generation strength.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue contracted 9.5% YoY in 2026Q3 to $5.0B, yet gross margin expanded to 46.5% from 45.7% sequentially, indicating pricing power and mix benefits despite volume declines.
BDX's forward P/E ratio of 12.82-13.44 suggests potential undervaluation compared to its trailing P/E of 34.55-35.03, indicating earnings growth expectations.
Multiple bullish theses from reputable sources like MoneyShow and Value Don't Lie highlight institutional confidence in BDX's growth prospects.
Appointment of long-time executive Vitor Roque as CFO demonstrates continuity in leadership and strategic execution.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $4.15+2.0% vs $4.07 | $5.3B+3.1% vs $5.1B |
Q3 2026 Aug 6, 2026 | $3.23+2.9% vs $3.14 | $5.0B+2.0% vs $4.9B |
Q2 2026 May 7, 2026 | $2.90+4.3% vs $2.78 | $4.7B+0.9% vs $4.7B |
Q1 2026 Feb 9, 2026 | $2.91+31.7% vs $2.21 | $4.5B-12.8% vs $5.1B |
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's, while others spotted fresh opportunities worth a closer look.
Benchmark BDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Becton, Dickinson and Company (BDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% | |
| $25.79 | $13.32B | -18.55 | 5.72% | -6.23% | -11.67% | 2.63% | |
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% |
Becton, Dickinson and Company (BDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Becton, Dickinson and Company (BDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 22, 2026·SEC
May 29, 2026·SEC
Get notified when BDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Becton, Dickinson and Company (BDX) stock FAQ — growth, dividends, profitability & financials explained
Becton, Dickinson and Company (BDX) reported $20.22B in revenue over the trailing twelve months. Revenue was $19.46B in fiscal year 2026. That is 592% more than the $2.81B of fiscal year 1997.
Becton, Dickinson and Company (BDX) revenue fell by 7.4% over the trailing twelve months, compared with the twelve months before.
Yes. Becton, Dickinson and Company (BDX) earned $1.14B in net income over the trailing twelve months (a 5.7% net margin).
Yes. Becton, Dickinson and Company (BDX) pays a dividend that yields 1.96% at the current price, a moderate yield.
Becton, Dickinson and Company (BDX) had a return on equity (ROE) of 3.7% over the trailing twelve months. That is below the market's typical 10-15%.
Becton, Dickinson and Company (BDX) generated $2.81B in free cash flow over the trailing twelve months.
